Companies › VLP Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VRP-encapsulated saRNA encoding IL-12 (VLPONC-01) Viral replicon particle (saRNA) expressing IL-12 | IL12 | Phase 1 | Head and Neck Cancers- Squamous Cell | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06736379 | VRP-encapsulated saRNA encoding IL-12 (VLPONC-01) | Phase 1 | Head and Neck Cancers- Squamous Cell | Oncology | Dec 2027 |
Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.